Arrowgrass Capital Partners (US)’s Vertex Pharmaceuticals VRTX Stock Holding History

Arrowgrass Capital Partners (US)’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q4	–	Sell	-199,200	Closed	-$24M	–	470
2015 Q3	$20.7M	Buy	199,200 +117,200	+143%	+$15.1M	0.39%	48
2015 Q2	$10.1M	Buy	82,000 +54,500	+198%	+$6.87M	0.15%	135
2015 Q1	$3.24M	Buy	27,500 +12,500	+83%	+$1.5M	0.05%	206
2014 Q4	$1.78M	Sell	15,000 -5,000	-25%	-$563K	0.03%	255
2014 Q3	$2.25M	Buy	+20,000	New	+$1.9M	0.05%	174
2013 Q4	–	Sell	-282,332	Closed	-$21.4M	–	197
2013 Q3	$21.4M	Buy	+282,332	New	+$22.5M	0.8%	32

Other funds holding VRTX

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

Arrowgrass Capital Partners (US)'s VRTX Position: Q4 2015 in Review

Arrowgrass Capital Partners (US) sold out of Vertex Pharmaceuticals (VRTX) in Q4 2015, closing a stake of 199,200 shares — an estimated $24M sold.

Arrowgrass Capital Partners (US) first reported a position in VRTX in Q3 2013 and held it in 6 quarters. The position peaked at $21.4M in Q3 2013. 518 funds tracked by Wall St. Rank hold VRTX as of Q4 2015.

Arrowgrass Capital Partners (US) reported no remaining Vertex Pharmaceuticals position as of Q4 2015 after selling out during the quarter.
Arrowgrass Capital Partners (US) sold 199,200 Vertex Pharmaceuticals shares in Q4 2015, an estimated $24M.
Arrowgrass Capital Partners (US) first reported a position in Vertex Pharmaceuticals in Q3 2013 and held it in 6 quarters.
Arrowgrass Capital Partners (US)'s Vertex Pharmaceuticals position peaked at $21.4M in Q3 2013.
518 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q4 2015.

Based on Arrowgrass Capital Partners (US)'s 13F filing for Q4 2015, filed 16 Feb 2016.